he article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p

Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series.

A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be coming on line soon.

Enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton.

Funding will support the development of new research infrastructure for screening and optimization of potential drug candidates...

RVX will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST.

This initiative will provide the necessary investments to advance apabetalone for potential treatment of Covid in the Arab-African Economy

Algernon Pharmaceuticals Selects NP-120 (Ifenprodil) for its Lead Phase 2 Trial for Idiopathic Pulmonary Fibrosis and Chronic Cough.. VANCOUVER, British Columbia, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct its first phase 2 clinical trial of its repurposed drug NP-120 (Ifenprodil) for

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110% VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that NP-120 (Ifenprodil), its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis